Volume Todays L/H More
Emkay Global Financial\’s report on Star Health
Our high-conviction Buy on Star Health is underpinned by three factors: 1) health insurance industry is still in its infancy – we expect heady growth rates of ~20% in the next decade; 2) Star Health\’s dominant market share (>3x nearest competitor) in the sticky retail sector offers network effects – trio of hospitals, customers and agents feed off each other in a virtuous cycle. Sub-scale competitors will struggle to outdo this moat; and 3) we expect margin gains with scale. We estimate Star Health\’s GWP to see a 25% CAGR through FY25. Unit economics are extremely favorable – we expect ROE of 18%+ as claims normalize in a 66-67% band (after Covid-19 hump), capping combined ratio at 94-95%. We apply a DCF model to arrive at our Mar\’23E TP of Rs1,135. We are of the view that investors should not be deterred by high valuations, which are rightfully anchored to STARHEALTH\’s nearly unassailable position in a high-growth industry.
We initiate coverage on STARHEALTH with a Buy rating and a Mar\’23 TP of Rs1,135 (+25% upside). Our TP implies a valuation multiple of 47x FY25E EPS and a FY25 P/GWP of 2.9x.
For all recommendations report, click here
- Buy Mayur Uniquoters: target of Rs 737: Sharekhan
- Buy Aarti Industries: target of Rs 1155: Sharekhan
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.